GalNAc-L96 – A Key Molecule for Efficient RNA Targeted Delivery
Introduction to GalNAc-L96
GalNAc-L96 (CAS 1159408-62-4) is a triantennary N-acetylgalactosamine (GalNAc) ligand primarily used for the synthesis of GalNAc-siRNA. GalNAc is a specific ligand for ASGPR (Asialoglycoprotein Receptor), enabling liver-targeted delivery, which is a crucial aspect of modern RNA delivery technology. Applications and Advantages of GalNAc-L96
Precise Liver-Targeted Delivery: ASGPR is highly expressed on liver cell surfaces, allowing siRNA, antisense oligonucleotides (ASO), or other nucleic acid drugs conjugated with GalNAc-L96 to efficiently enter liver cells and enhance therapeutic effects.
Enhanced Bioavailability of siRNA: Traditional siRNA delivery methods (such as lipid nanoparticles, LNPs) often lead to non-specific distribution, whereas GalNAc-conjugated siRNA (GalNAc-siRNA) enables more efficient and safer RNA interference (RNAi) therapy.
Reduced Systemic Toxicity: Due to the high specificity of GalNAc delivery, compared to LNPs, GalNAc-siRNA exhibits lower immunogenicity and reduced side effects, making it a preferred strategy for RNA drug development.
Improved Stability and Optimized Pharmacokinetics: By optimizing the structure of GalNAc-L96, its affinity for ASGPR can be enhanced, thereby increasing hepatic cell uptake and prolonging in vivo half-life.
Watson’s Unique Advantages in the GalNAc Field
Advanced Synthesis Techniques and Purity Control
Watson leverages cutting-edge glycochemistry and nucleic acid modification technologies to provide high-purity, high-quality GalNAc-L96 and its derivatives, ensuring optimal outcomes in RNAi and ASO drug development.
Comprehensive Support from Lab to Industrial Scale
Watson not only supplies small-scale research-grade products but also has pilot and industrial-scale production capabilities, meeting the demands from early-stage research to clinical production.
Strict adherence to quality management systems (ISO certification) ensures product quality and stability.
Strong Technical Expertise and Industry Recognition
With years of experience in glycoconjugates and RNA delivery, Watson collaborates with leading pharmaceutical and biotechnology companies worldwide, driving advancements in RNA therapeutics.
Watson’s high-end customization and innovative synthesis capabilities make it a key global partner in RNA delivery technologies.
Conclusion
As a core ligand for RNA-targeted delivery, GalNAc-L96 plays a vital role in siRNA and ASO therapies. With cutting-edge synthesis technologies, strict quality control, and strong customization capabilities, Watson holds a distinct competitive advantage in this field, supporting breakthroughs in RNA delivery technology.
If you are interested in GalNAc-related products or RNA delivery solutions, feel free to contact Watson for more information!
As a core ligand for RNA-targeted delivery, GalNAc-L96 plays a vital role in siRNA and ASO therapies. With cutting-edge synthesis technologies, strict quality control, and strong customization capabilities, Watson holds a distinct competitive advantage in this field, supporting breakthroughs in RNA delivery technology.
If you are interested in GalNAc-related products or RNA delivery solutions, feel free to contact Watson for more information! 
![structure of 2,5-Diethoxy-4-[(4-methylphenyl)thio]-benzenediazonium tetrachlorozincate CAS 38656-51-8](https://www.watson-int.com/wp-content/uploads/2023/06/structure-of-25-Diethoxy-4-4-methylphenylthio-benzenediazonium-tetrachlorozincate-CAS-38656-51-8-150x150.png)
![structure of N,N'-Bis[4-(diphenylamino)phenyl]-N,N'-di-1-naphthalenyl-[1,1'-biphenyl]-4,4'-diamine CAS 910058-11-6](https://www.watson-int.com/wp-content/uploads/2015/07/structure-of-NN-Bis4-diphenylaminophenyl-NN-di-1-naphthalenyl-11-biphenyl-44-diamine-CAS-910058-11-6-150x150.png)
